Hosted on MSN1h
Merck's RSV Shot Cuts Infant Hospitalizations by Over 80% in Trial, Eyes 2025 Launch
Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...
Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...
Investors in Merck (NYSE:MRK) have seen respectable returns of 48% over the past three years
It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen ...
Merck RSV therapy cuts respiratory infections by 60% in infants
Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...
Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...
Merck posts positive trial data for Capvaxive pneumonia vaccine in at-risk adults
Merck (MRK) says it Capvaxive vaccine showed positive immune responses in a Phase 3 trial for adults at risk for pneumonia.
TMCnet2d
Nodenza Venture Partners launched - focus on international early-stage and pre-commercial biotech & medtech opportunities
Focus on international early-stage and pre-commercial biotech & medtech opportunities ...
clinicaltrialsarena3d
Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint
Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.
TMCnet3d
Transpire Bio Strengthens Leadership Team with New Appointments to Lead Commercialization, Quality Assurance, and Manufacturing
With the recent expansion of our research and manufacturing capabilities, it is the perfect time to bring additional expertise to our leadership team in the critical areas of commercialization, ...
Up 700% This Year, Is It Too Late to Invest in This Stock?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
clinicaltrialsarena3d
Exelixis and MSD to trial cancer therapies together in clinical collaboration
Merck Research Laboratories global clinical development oncology senior vice-president and head Dr Marjorie Green said: “We look forward to working with our colleagues at Exelixis to advance these ...
2 Incredibly Cheap Big Pharma Stocks to Buy Now
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.